MYC and neoplasm: A non-randomized, open-label phase II trial of arginine deiminase in ASS1-low SCLC patients was terminated due to slow patient accrual and lack of tumor response after 22 patients had been enrolled, though patient stratification based on factors such as MYC expression may be beneficial [101].